drugset / Trial / NCT00117208

Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis

NCT00117208

Phase 2 Completed 20 enrolled Syntara
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.

Timeline

Start
2005-11
Primary completion
2008-02
Completion
2008-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent 400 mg Inhaled
Comparator dornase alfa Protein / enzyme biologic 2.5 mg Inhaled

Indications